Regeneron Pharmaceuticals, Inc.

NasdaqGS-REGN

OverviewFinancialsInvestor RelationsResearchEstimatesNewsOwnershipIndustryDividendsModelingFilings

Assets	LTM	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
Cash and Cash Equivalents	2,506.4	2,488.2	2,730	3,105.9	2,885.6	2,193.7	1,617.8	1,467.7	812.7	535.2	809.1
Cash and Cash Equivalents
Short-Term Investments	5,937.2	6,524.3	8,114.8	4,636.4	2,809.1	1,393.3	1,596.5	1,342.2	596.8	503.5	236.1
Marketable Securities
Total Cash and Cash Equivalents	8,443.6	9,012.5	10,844.8	7,742.3	5,694.7	3,587	3,214.3	2,809.9	1,409.5	1,038.7	1,045.2
Accounts Receivable	5,687.1	6,211.9	5,667.3	5,328.7	6,036.5	4,114.7	2,360.6	2,243.2	1,974.3	1,611.6	1,467.8
Accounts Receivable - Trade, Net
Accounts Receivable from Sanofi
Accounts Receivable from Bayer HealthCare
Accounts Receivable from Bayer
Accounts Receivable - Sanofi, Net
Accounts Receivable, Net
Other Receivables	—	—	—	—	—	—	425	—	—	—	—
Accounts Receivable - Other
Accounts Receivable - Other, Net
Total Trade Receivables	5,687.1	6,211.9	5,667.3	5,328.7	6,036.5	4,114.7	2,785.6	2,243.2	1,974.3	1,611.6	1,467.8
Inventories	3,254.4	3,087.3	2,580.5	2,401.9	1,951.3	1,916.6	1,415.5	1,151.2	726.1	399.4	238.6
Inventories
Other Current Assets	595.6	349.2	386.6	411.2	332.4	160.8	273.7	243.3	225.1	130.5	163.5
Deferred Tax Assets
Prepaid Expenses and Other Current Assets
Total Current Assets	17,980.7	18,660.9	19,479.2	15,884.1	14,014.9	9,779.1	7,689.1	6,447.6	4,335	3,180.2	2,915.1
Total Current Assets
Net Property, Plant & Equipment	5,002.3	4,599.7	4,146.4	3,763	3,482.2	3,221.6	2,890.4	2,575.8	2,358.6	2,083.4	1,594.1
Property, Plant, and Equipment, Net
Net Intangible Assets	1,380.9	1,148.6	1,038.6	915.5	6.7	—	—	—	—	—	—
Intangible Assets, Net
Long-Term Investments	10,285.7	8,900.1	5,396.5	6,591.8	6,838	3,135.6	3,256.8	1,755	1,486.5	864.3	632.2
Marketable Securities
Other Long-Term Assets	5,519.8	4,450.1	3,019.5	2,060.1	1,093	1,027	968.9	956.1	584.2	845.6	467.8
Restricted Cash and Marketable Securities
Deferred Tax Assets
Other Assets
Other Noncurrent Assets
Total Assets	40,169.4	37,759.4	33,080.2	29,214.5	25,434.8	17,163.3	14,805.2	11,734.5	8,764.3	6,973.5	5,609.1
Total Assets

Liabilities	LTM	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
Accounts Payable	903.8	789.5	606.6	589.2	564	475.5	418.1	218.2	178.2	879.1	644.1
Accounts Payable and Accrued Expenses
Accounts Payable
Accrued Expenses	2,975.7	2,527.1	2,357.9	2,074.2	2,206.8	1,644.2	1,211.4	772.1	637.2	—	—
Accrued Expenses and Other Current Liabilities
Short-Term Debt	—	—	—	—	—	—	—	—	—	—	—
Debt
Current Portion of Leases	—	—	—	—	719.7	—	—	—	—	129.6	—
Finance Lease Liabilities
Unearned Revenue	545.6	627.7	458.9	477.9	442	577.7	382.1	452.5	320.1	231.7	153.5
Deferred Revenue - Sanofi
Deferred Revenue - Other
Deferred Revenue
Deferred Revenue - Other, Current Portion
Other Current Liabilities	—	—	—	—	—	—	85	—	—	1.2	13.6
Other Liabilities - Sanofi
Other Current Liabilities
Total Current Liabilities	4,425.1	3,944.3	3,423.4	3,141.3	3,932.5	2,697.4	2,096.6	1,442.8	1,135.5	1,241.5	811.2
Total Current Liabilities
Long-Term Debt	1,985.5	1,984.4	1,982.9	1,981.4	1,980	1,978.5	—	—	—	—	—
Long-Term Debt
Leases	720	720	720	720	—	717.2	713.9	708.5	703.5	351.6	362.9
Finance Lease Liabilities
Other Long-Term Liabilities	2,081	1,757.1	980.8	707.8	753.5	744.9	905	825.9	781.2	931.2	780.2
Deferred Revenue - Other
Other Liabilities - Sanofi
Deferred Revenue from Sanofi
Deferred Revenue - Sanofi
Deferred Revenue
Other Noncurrent Liabilities
Deferred Revenue from Sanofi-Aventis
Total Long-Term Liabilities	4,786.5	4,461.5	3,683.7	3,409.2	2,733.5	3,440.6	1,618.9	1,534.4	1,484.7	1,282.7	1,143.1
Total Liabilities	9,211.6	8,405.8	7,107.1	6,550.5	6,666	6,138	3,715.5	2,977.2	2,620.2	2,524.2	1,954.3
Total Liabilities

Equity	LTM	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
Common Stock	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Class a Stock, Convertible
Common Stock
Treasury Stock	-17,944.4	-15,167.4	-12,560.4	-10,353.3	-8,260.9	-6,613.3	-739.9	-396.4	-316.2	-316.2	-306.1
Treasury Stock, at Cost
Additional Paid-in Capital	13,787.3	12,855.9	11,354	9,949.3	8,087.5	6,716.2	4,428.6	3,911.6	3,512.9	3,030	3,099.5
Additional Paid-in Capital
Accumulated Other Comprehensive Income	69	-7.9	-80.9	-238.8	-26.2	29.3	21.1	-12.3	0.6	-12.8	8.6
Accumulated Other Comprehensive Income
Retained Earnings	35,045.8	31,672.9	27,260.3	23,306.7	18,968.3	10,893	7,379.8	5,254.3	2,946.7	1,748.2	852.7
Unearned Compensation
Retained Earnings
Total Common Shareholders' Equity	30,957.8	29,353.6	25,973.1	22,664	18,768.8	11,025.3	11,089.7	8,757.3	6,144.1	4,449.2	3,654.8
Total Stockholders' Equity
Total Shareholders' Equity	30,957.8	29,353.6	25,973.1	22,664	18,768.8	11,025.3	11,089.7	8,757.3	6,144.1	4,449.2	3,654.8
Total Liabilities and Shareholders' Equity	40,169.4	37,759.4	33,080.2	29,214.5	25,434.8	17,163.3	14,805.2	11,734.5	8,764.3	6,973.5	5,609.1
Total Liabilities and Stockholders' Equity